PharmaExcess enables pharmaceutical companies to sell excess inventory such as APIs, intermediates, excipients, solvents, laboratory equipment and plant machinery. Surplus inventory may arise due to regulatory observations, demand forecast changes, procurement mismatches, plant upgradations among others, or simply a Balance Sheet cleanup exercise.
Buyers can source quality pharmaceutical materials confidentially with structured price discovery and documentation visibility.
No listings available at the moment.
Yes, surplus pharmaceutical materials can be sold subject to regulatory compliance.
Buyer and seller identities remain anonymous until commercial agreement.
APIs, intermediates, excipients, solvents and reagents, reactors, vessels, packaging machinery, laboratory equipment and utilities and spares.
Pharmaceutical manufacturers often generate surplus stock due to product discontinuation, export rejection, forecast variation, regulatory observations or plant capacity optimisation. Efficient liquidation of such inventory helps improve working capital cycle and warehouse utilisation.
PharmaExcess enables structured buyer discovery and competitive pricing while maintaining confidentiality and documentation integrity.